SCHEMBL6797109

SCHEMBL6797109

Cc1ccc(S(=O)(=O)CC[Si](C)(C)C)cc1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.64
CYP2C19 P33261 2/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2C9 P11712 1/20 0.64
KMT2A Q03164 6/20 0.54
NPC1 O15118 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
PAX8 Q06710 1/20 0.45
ADAM17 P78536 1/20 0.45
CTSK P43235 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL41372 0.83 ALDH1A1 (0.82) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8071225 0.82 PSIP1 (0.56) ALDH1A1KMT2ASMN1; SMN2MEN1MAPT
SCHEMBL1582969 0.79 ALDH1A1 (0.91) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL1820762 0.79 ALDH1A1 (1.00) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL5463183 0.77 ALDH1A1 (0.87) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8742947 0.77 ALDH1A1 (0.72) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL4001371 0.77 ALDH1A1 (0.87) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8970657 0.77 ALDH1A1 (0.87) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8971703 0.77 ALDH1A1 (0.87) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8971430 0.77 ALDH1A1 (0.87) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6774126-B2 Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors PHARMACIA CORPORATION 2004-08-10 US disclosed
US-20040019019-A1 Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors PHARMACIA CORPORATION 2004-01-29 US disclosed
US-6552052-B2 (2S,3Z)-2-amino-5-(6,7,8,9-tetrahydro-3-oxo-3H,5H -(1,2,4)oxadiazolo(4,3-a)azepin-5-yl)-3-pentenoic acid, for example MONSANTO/G.D. SEARLE 2003-04-22 US disclosed
US-6489323-B1 INHIBITING NO PRODUCTION FROM L-ARGININE, AS SEEN IN DISEASE STATES SUCH AS ARTHRITIS AND SYSTEMIC HYPOTENSION ASSOCIATED WITH SEPTIC AND/OR TOXIC SHOCK G.D. SEARLE & CO. 2002-12-03 US disclosed
US-20010044539-A1 Heterobicyclic and tricyclic nitric oxide synthase inhibitors HANSEN DONALD W (US) 2001-11-22 US disclosed
EP-1086108-A1 HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS G.D. Searle & Co. (US) 2001-03-28 EP disclosed
WO-1999064426-A1 HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010044539-A1 Heterobicyclic and tricyclic nitric oxide synthase inhibitors NOS1, NOS2, NOS3 ALDH1A1 1337/4885CYP2C19 54/4885CYP3A4 78/4885
US-20040019019-A1 Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors NOS1, NOS2, NOS3 ALDH1A1 358/4885CYP2C19 277/4885CYP3A4 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.